Literature DB >> 1203874

Hemangiopericytoma. A clinicopathologic study and long-term followup of 60 patients.

M J McMaster, E H Soule, J C Ivins.   

Abstract

The clinical courses of 60 patients with hemangiopericytoma of the somatic soft tissues are summarized in this retrospective study. The tumors were subjected to a comparative histologic review and classified as benign (12 lesions), borderline malignant (16 lesions), and malignant (32 lesions). Tumors with 1 mitotic figure per 10 high-power field and moderate cellular anaplasia or 1 mitotic figure per 20 high-power fields and moderate cellular anaplasia may be expected to follow a malignant clinical course. Six of the 16 tumors with these microscopic features (borederline lesions) metastasized (37.5%), and 6 exhibited local recurrences after excision. Of the 32 malignant tumors, 25 (78%) metastasized. Twenty-three patients with malignant tumors were followed for more than 5 years or until death from tumor, and only one patient was alive and free of disease. Fifteen of the 23 patients experienced one of more local recurrences. None of the benign tumors metastasized. Surgical ablation of hemangiopericytioma is, in our experience, the only satisfactory method of treatment. Amputation of an extremity need be done only when the location of the lesion precludes a wide local excision. Local recurrent tumor was experienced by 22 patients after an inadequate local excision. Long-term follow-up is recommended because metastasis became apparent in 11% of patients with malignant tumors and 7% with borderline tumors after 5 "disease-free" years.

Entities:  

Mesh:

Year:  1975        PMID: 1203874     DOI: 10.1002/cncr.2820360942

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  64 in total

1.  Primary omental haemangiopericytoma.

Authors:  Gareth Morris-Stiff; Gavin A Falk; Daniel Joyce; Brian Rubin; Sricharan Chalikonda
Journal:  BMJ Case Rep       Date:  2011-05-24

2.  Surgically treated bladder hemangiopericytoma/solitary fibrous tumor: report of a 12-year asymptomatic follow-up.

Authors:  Sarah Mozafarpour; Reza Khorramirouz; Afshin Tajali; Alborz Salavati; Abdol-Mohammad Kajbafzadeh
Journal:  Int Urol Nephrol       Date:  2014-03       Impact factor: 2.370

3.  A giant paraspinal hemangiopericytoma and its preoperative embolization.

Authors:  M O Cizmeli; E T Ilgit; H Ulug; A Erdogan
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

Review 4.  Spinal hemangiopericytoma: an institutional experience and review of literature.

Authors:  Amitabha Das; Pankaj Kumar Singh; Vaishali Suri; Mukund N Sable; Bhawani Shankar Sharma
Journal:  Eur Spine J       Date:  2015-02-08       Impact factor: 3.134

5.  Hemangiopericytoma of thoracic spine: a rare bony tumor.

Authors:  Raj Kumar; Vivek Kumar Vaid; Vimal Kumar; Samir Kumar Kalra
Journal:  Childs Nerv Syst       Date:  2007-05-31       Impact factor: 1.475

6.  Intraspinal hemangiopericytoma: case report and review of the literature.

Authors:  M Salvati; P Ciappetta; M Artico; A Raco; A Fortuna
Journal:  Neurosurg Rev       Date:  1991       Impact factor: 3.042

7.  Giant haemangiopericytoma of the uterus.

Authors:  Purvita Dam; Sudip Kumar Saha; Sharmistha Banerjee; Sourav Ganguly
Journal:  J Obstet Gynaecol India       Date:  2012-03-07

8.  A rare tumor at the elbow: a glomangioma. Differential diagnosis and therapy.

Authors:  W H Castro; C W de Fijter; O J Kronig; J Koudstaal; A Labrie; W Winkelmann
Journal:  Arch Orthop Trauma Surg       Date:  1989       Impact factor: 3.067

9.  Liver recurrence of a subcutaneous temporal hemangiopericytoma: the index case.

Authors:  Stéphane Zalinski; Claire Goumard; Olivier Scatton; Benoit Terris; Francoise Plantier; Nicolas Dupin; Olivier Soubrane
Journal:  J Gastrointest Surg       Date:  2009-01-16       Impact factor: 3.452

Review 10.  Resection of primary pulmonary hemangiopericytoma: a report of two cases.

Authors:  M Kuroya; H Yokomise; K Inui; O Ike; H Mizuno; H Wada; S Hitomi
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.